BRT Laboratories, Inc. Has Been Approved As A Clinical Trial Testing Facility For OncoMethylome Sciences S.A.’ Participation In A Multi-Site, International Clinical Trial

BRT Laboratories, Inc. announced today that the laboratory has been approved by the clinical trial supporter and OncoMethylome Science’s collaborator, Schering-Plough Corporation, to provide MGMT methylation testing for OncoMethylome Sciences. Starting immediately, the laboratory will be evaluating the methylation status of the MGMT gene in DNA extracted from brain tumor cells using OncoMethylome Sciences’ patent-protected assay.